Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities

BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to...

Read more: Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activitie...

More Articles …

  1. Australian Hyundai NEXO breaks world distance record
  2. With Blackbaud Peer-to-Peer Fundraising™, powered by JustGiving®, Australia and New Zealand Social Good Organisations Can Transform Supporters into Advocates
  3. Crazy Domains Launches "Your Business is Better Off Online" - Confronting the Challenges 1.2 million Australian SMBs Face Today
  4. Crazy Domains Addresses the Challenge New Zealand SMBs Face with Multi-Channel Campaign
  5. KX Partners With Databricks To Bring Ultra-Real-Time Decision Making To Lakehouse Platform
  6. Report Reveals Customers Dominate but Employees Edge Out Investors and the Board as Key Stakeholders, According to Russell Reynolds Associates
  7. Winners in 2021 Asia-Pacific Stevie Awards Announced
  8. Julius Meinl Coffee Makes Up for Year's 'Most Missed Moment' With 'Say Hello' Campaign
  9. Shaemus Gleason Appointed Executive Vice President US Operations at Clarity Pharmaceuticals
  10. Enapter preparing AEM Multicore for 2022 launch